Haemonetics Corporation (HAE) Given Coverage Optimism Rating of 0.25
News articles about Haemonetics Corporation (NYSE:HAE) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Haemonetics Corporation earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned media coverage about the medical instruments supplier an impact score of 47.9184620163349 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- See what the IHS Markit Score report has to say about Haemonetics Corp. (finance.yahoo.com)
- Research Analysts Set Expectations for Haemonetics Corporation’s Q3 2018 Earnings (NYSE:HAE) (americanbankingnews.com)
- Haemonetics Corporation (HAE) Rating Increased to B- at TheStreet (americanbankingnews.com)
- Haemonetics Corporation (NYSE:HAE) Sees Heavy Trading Volume with 705K Shares Changing Hands (highlightpress.com)
- Haemonetics Corporation (HAE) Upgraded to “Outperform” by Barrington Research (americanbankingnews.com)
Shares of Haemonetics Corporation (NYSE HAE) traded up 1.97% during mid-day trading on Friday, reaching $42.50. The company had a trading volume of 287,171 shares. Haemonetics Corporation has a one year low of $32.76 and a one year high of $43.74. The firm has a market capitalization of $2.24 billion, a price-to-earnings ratio of 551.95 and a beta of 0.90. The stock has a 50 day moving average of $40.24 and a 200-day moving average of $40.17.
Haemonetics Corporation (NYSE:HAE) last released its earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.02. The business had revenue of $211 million for the quarter, compared to analyst estimates of $211.29 million. Haemonetics Corporation had a net margin of 0.48% and a return on equity of 11.07%. Haemonetics Corporation’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.25 earnings per share. Equities analysts predict that Haemonetics Corporation will post $1.61 EPS for the current year.
A number of research analysts have recently weighed in on the company. Zacks Investment Research downgraded Haemonetics Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, May 9th. Jefferies Group LLC reissued a “buy” rating and issued a $42.00 price target on shares of Haemonetics Corporation in a research note on Monday, May 8th. TheStreet raised Haemonetics Corporation from a “c” rating to a “b-” rating in a research note on Monday, August 7th. BidaskClub raised Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a research note on Tuesday. Finally, Barrington Research raised Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 price target on the stock in a research note on Tuesday. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $40.63.
ILLEGAL ACTIVITY NOTICE: This story was first posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/08/12/haemonetics-corporation-hae-given-coverage-optimism-rating-of-0-25.html.
In related news, Director Ronald Merriman sold 17,471 shares of the business’s stock in a transaction on Monday, May 22nd. The shares were sold at an average price of $40.33, for a total value of $704,605.43. Following the transaction, the director now owns 24,925 shares in the company, valued at $1,005,225.25. The transaction was disclosed in a document filed with the SEC, which is available through this link. 1.20% of the stock is owned by insiders.
Haemonetics Corporation Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.